Investigating the causes of blood platelet defects and related health issues.
Official title: Developmental causes of syndromic Thrombocytopenia and co-morbidities
Funded at University of Colorado Denver · NIH-10850978 · Data updated 2026-11-12
This study is looking into how certain genetic factors during early development can lead to low platelet counts and related health issues, with the hope that the findings will help improve diagnosis and treatment for patients with these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | September 1, 2022 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $223,920 |
| NIH project number | 5R01DK129350-03 |
| Project ID | NIH-10850978 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals diagnosed with syndromic thrombocytopenia or related congenital hematopoietic disorders.
✕Less likely to help
Patients with non-syndromic thrombocytopenia or those without any hematological disorders may not receive direct benefits from this research.
What this research studies
This research focuses on understanding the developmental origins of syndromic thrombocytopenia, a condition characterized by low blood platelet counts and associated health problems. By examining the embryonic development of blood precursor cells and their connection to other organ systems, the study aims to uncover the genetic and biological mechanisms behind these disorders. The research utilizes advanced techniques such as CRISPR to manipulate genes and observe their effects on development in model organisms. Patients may benefit from insights that could lead to improved diagnosis and treatment options for related conditions.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and management of syndromic thrombocytopenia and its associated health issues.
How similar studies have gone: Previous research has shown promise in understanding genetic contributions to hematopoietic disorders, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Burger, Alexa — University of Colorado Denver
- Study coordinator: Burger, Alexa
Related research
Other NIH-funded projects on the same topics.
-
New ideas to understand, diagnose, and treat heparin-induced thrombocytopenia
A Mayo Clinic led study will look at the different kinds of HIT antibodies to improve diagnosis and treatment for people with HIT.
-
Second-generation BLVRB inhibitors to help chemotherapy patients with low platelets
A new drug candidate is being developed to raise platelet counts in patients whose cancer treatment lowers them, reducing bleeding risk.
-
Immunobiology of vaccine-related clotting after adenovirus vaccines
This research asks how antibodies linked to a rare vaccine-related clotting condition (VITT) interact with specific blood proteins to cause clots after certain COVID-19 vaccines.
-
Understanding and diagnosing Heparin-Induced Thrombocytopenia (HIT)
A project to understand the immune factors behind HIT and develop faster, more accurate tests to help people who need heparin therapy.
-
Fetal and neonatal platelet allergy: understanding why some babies bleed
A study to understand why maternal antibodies cause serious bleeding in babies with FNAIT, using an animal model and human-relevant clues to improve future care for affected families.
-
Molecular mechanisms behind immune-related low platelets and clots in transfusion medicine
This grant supports a team of researchers to understand how immune factors cause low platelets and abnormal clots, with a focus on transfusion medicine and pediatric to adult patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.